@article{Ravasio_Giacomelli_Bianchi_2020, title={Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease: Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia}, volume={7}, url={https://journals.aboutscience.eu/index.php/grhta/article/view/2140}, DOI={10.33393/grhta.2020.2140}, abstractNote={<p><strong>Background</strong>: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab.</p> <p><strong>Objective</strong>: Aim of this study was to estimate the budget impact of the use of anakinra compared to canakinumab and tocilizumab in the treatment of patients with AOSD or SJIA.</p> <p><strong>Methods</strong>: Considering the perspective of the Italian National Health Service (iNHS), a budget impact model (BIM) was developed to estimate the drugs costs of anakinra, canakinumab and tocilizumab up to 12 months. The BIM showed the difference of drug expenditure generated by the base case calculated for current prescription volumes, and for different prescription volume scenarios with increased anakinra prescription. Key variables were tested in the sensitivity analysis.</p> <p><strong>Results</strong>: Compared to the current scenario for SJIA, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€1,118,005 [-12.7%] or -€2,054,502 [-23.4%]). Compared to the current scenario for AOSD, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€4,024,585 [-13.5%] or -€8,049,169 [-27.0%]).</p> <p><strong>Conclusion</strong>: According to the present analysis, the use of anakinra, as an alternative to canakinumab or tocilizumab in patients with AOSD or SJIA, could represent a cost-saving option for the iNHS.</p>}, number={1}, journal={Global and Regional Health Technology Assessment}, author={Ravasio, Roberto and Giacomelli, Roberto and Bianchi, Stefano}, year={2020}, month={Sep.}, pages={72–80} }